

RhôneAlpes^{Région}



VIRGIL



COMBATTING VIRAL RESISTANCE TO TREATMENTS

VIRGIL is a European Network of Excellence funded by the European Commission within Priority 1 "Life Sciences, Genomics and Biotechnology for Health" of the 6th Frame Work Programme

For more information visit our website: <http://www.virgil-net.org/>

Second VIRGIL International Symposium on Antiviral Drug Resistance

Tuesday May 23rd, 2006

Lyon, France, free event

Final Program

***Contact for registration: Natacha
Edme,
natacha.edme@tolbiac.inserm.fr***

9.00 am : Welcome : ■ F Zoulim (Inserm, Lyon), ■ J Weinbach (Inserm-Transfert, Paris)

Opening Presentation : VIRGIL, the European Network of Excellence on Antiviral Drug Resistance – **Achievements after two years of existence**, ■ F Zoulim (Inserm, Lyon)

New drugs and clinical impact of drug resistance

Chairs : ■ Christian Trepo (Inserm, Lyon, France), ■ Jean-Marie Cohen (Open-Rome, Paris, France)

Invited speaker: ■ Erik De Clercq (Rega Institute Leuven, Belgium) : *New antiviral drugs for HBV, HCV, HIV and influenza viruses*

■ Bruno Lina (University C Bernard Lyon, France): Drug resistant mutants of influenza virus and avian flu

■ Michael Manns / Heiner Wedemeyer (University of Hannover, Germany): Management of non response to anti-HCV therapy

■ Solko Schalm (Erasmus University Rotterdam, the Netherlands) : Clinical case management of HBV Resistance to therapy

Diagnosis of drug resistance

Chairs : ■ Jean Michel Pawlotsky (Inserm, France) - ■ Maria Zambon (HPA, The United Kingdom)

Invited speaker- François Clavel (Inserm, Paris, France) : *Mechanisms of HIV drug resistance*

■ Willy Spaan (LUMC, Leiden, The Netherlands): Drug targets for SARS coronavirus infection

■ Stephan Zeuzem (Saarland University, Homburg, Germany): Viral dynamics and treatment failure in Hepatitis C

■ Rafael Esteban (HU Vale Hebron, Barcelona, Spain): Diagnosis and management of HBV resistance

12.30 to 2.00 pm: Lunch break and visit of sponsors exhibition

Understanding drug resistance

Chairs : ■ Alan Hay (WHO Influenza Center, UK), ■ Ralf Bartenschlager (University of Heidelberg, Germany)

Invited speaker : ■ Bruno Canard, (Uni Marseille, France): *The Vizier program; Viral enzyme targets for the discovery of new antivirals*

■ John Oxford (Retroscreen London, UK) : Testing resistance to influenza drugs in the ferret model

Invited speaker : Takaji Wakita, (Tokyo Metropolitan Institute for Neuroscience , Japan) : *Development of new HCV replication model in tissue culture*

■ Joerg Petersen (University of Eppendorf, Hamburg, Germany): HBV resistance to antivirals: insight from experimental models

The immune system and drug resistance

Chairs : ■ Gerd Pape (LM University of Munich, Germany), ■ Stephan Ludwig (University of Giessen, Germany)

Invited speaker: Juergen Rockstroh (University of Bonn, Germany), *Antiviral therapy of HIV infection: current management of drug resistance*

■ Stephan Pleschka: Influenza virus and host-cell signaling: new targets for antiviral therapy

■ D. Mutimer (University of Birmingham, UK): Management of HBV resistance in transplanted patients

Invited speaker : G. Inchauspe (Transgene, France) : *Vaccine therapy of chronic hepatitis C*

End of the conference at 6.00 pm

Gala Dinner 7:30 pm

Nota Bene: Speakers with the ■ label are Members of the VIRGIL consortium
